GAITHERSBURG, Md., Dec. 7 /PRNewswire/ -- Sequoia Pharmaceuticals, Inc. announced today that it has submitted an investigational New Drug Application (IND) with the United States Food and Drug Administration to begin human clinical trials with SPI-452, a novel pharmacokinetic enhancer. SPI-452 is designed to improve the exposure of co-administered HIV medications thereby providing more efficacious, less toxic and more user-friendly drug regimens.
Sequoia’s first IND was submitted for its’ novel HIV protease inhibitor, SPI-256, in February 2007, and ongoing Phase I clinical trials continue to yield favorable results.
“I am very impressed with the accomplishments of the teams at Sequoia. To have discovered and developed two drug candidates within five years of founding and to submit two IND’s in one year is an outstanding demonstration of the commitment and capability of the entire organization. We look forward to further progress in human trials of these two novel therapeutic agents,” said Steven Skolsky, CEO of Sequoia.
About Sequoia:
Sequoia Pharmaceuticals is a private, venture capital funded company that discovers and develops revolutionary new treatments, primarily for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing problem of drug- resistant infectious diseases.
CONTACT: Gary Altman, COO, of Sequoia Pharmaceuticals, Inc.,
+1-240-632-0094 extension 102
Web site: http://www.sequoiapharma.com/
